18F-FDG PET is a molecular whole-body imaging modality that is increasingly being used
for diagnosing, staging, and restaging cancer. The objective of this study was to determine …

The value of performing follow-up PET/CT imaging more than 6 mo after the conclusion of
therapy—either as a routine practice or because of clinically suspected recurrence—is not …

Survival of lung cancer patients remains poor despite increasingly aggressive treatment.
Conventional staging has well-described limitations. 18F-FDG PET has been shown to …

18F-FDG PET is increasingly used for lung cancer; however, some insufficient results have
been reported. The purpose of this study was to evaluate the efficacy of dual–time-point 18F …

Whole-body PET with 18F-FDG has proven to be a very effective imaging modality for
staging of malignant tumors. This study was performed to evaluate the impact of 18F-FDG …

We previously reported aggregate data showing that PET was associated with a change in
intended management for over one third of patients participating in the National Oncologic …

Background: A study was undertaken to study the effect of 18F-fluorodeoxyglucose (FDG)
positron emission tomography (PET) on the diagnosis and management of clinically …

The aim of this study was to evaluate the impact of whole-body 18F-FDG PET on staging
and managing patients with small cell lung cancer (SCLC). Methods: The treatment records …

The aim of this study was to evaluate [18 F] fluorodeoxyglucose (18 F-FDG) imaging of
recurrent or inoperable lung cancer using a hybrid positron emission tomography (PET) …

The purpose of this study was to evaluate the value of an 18F-FDG PET/CT–based
interpretation system (Hopkins criteria) to assess the therapy response and survival in lung …